Foundation Medicine Inc. announced Monday a multi-year collaboration with pharmaceutical giant AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines.

Cambridge-based Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer.